TABLE 1.

Characteristics of included studies.

Article	Country	Study design	Tumor type	Sample size	Setting	Male (%)	PIMs criteria applied	Prevalence (%)		Quality of studies
								Polypharmacy	PIMs
Tian et al., 2022 [20]	China	Cross-sectional	Lung cancer	1,275	Outpatients	56.55	2019 AGS Beers criteria	17.88	42.67	7
Hakozaki et al., 2021 [21]	Japan	Retrospective study	Advanced lung cancer	232	Inpatients	25.86	STOPP/START V2	38.4	31.9	7
Ham et al., 2021 [22]	Netherland	Observational study	Lung cancer at the end of life	7,864	Outpatients	67.43	OncPal Deprescribing Guideline	54.82	28.41	7
Mohamed et al., 2021 [23]	America	Cross-sectional	Lung cancer with physical functional impairments	125	Inpatients	—	2015 AGS Beers criteria	48	—	7
Hakozaki et al., 2020 [24]	Japan	Cross-sectional	Advanced non-small-cell Lung cancer	157	Inpatients	63.69	STOPP/START V2	59.87	38.22	7
Lund et al., 2018 [25]	America	Cross-sectional	I–II Lung cancer	7,237	Inpatients	42.48	2012 AGS Beers criteria	33.30	37–45	7